BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to-severe atopic dermatitis (AD).

INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarter ended September 30, 2020.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that management will present at three upcoming virtual investor conferences:

Did you know that a microbiome can help protect your body metabolism along with your brains and gut? The antibiotics present in our body or received from an outer source may sometimes not be favorable for your body and may otherwise lower down the metabolism level and inflame the entire body.

The campaign targets communities most at risk for low screening rates, including Black and Hispanic populations, and those with high risk factors.

InControl Medical, LLC announced that the Centers for Medicare & Medicaid Services under the U.S. Department of Health and Human Services has authorized the Company to be a Medicare Provider.

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that the poster " A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12-month analysis of

ABEC’s fermentation systems to support growing demand for recombinant proteins for biotechnology research

POXEL SA announced that results from its Phase 1b study of PXL065 and results from three preclinical studies for PXL770 will be presented as e-posters at The Liver Meeting® 2020 hosted by the American Association for the Study of Liver Diseases, which will be held virtually from November 13-16, 2020.